Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.

What Was Tested

The paper reports a study of C-Peptide, published as a clinical trial.

At baseline and at 12 and 24 weeks after starting ipragliflozin treatment, a meal test was performed to evaluate the fasting and 2-hour proinsulin/C-peptide ratio.

Why It Was Studied

Chronic hyperglycemia has an adverse influence on beta-cell function, which is known as 'glucotoxicity'.

Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower the blood glucose concentration by enhancing urinary glucose excretion.

Who Took Part

According to the abstract, 19 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The subjects were 19 Japanese patients with type 2 diabetes.

How the Study Was Run

The design is described as open-label.

Nothing was hidden in this open-label C-Peptide study: the patients and staff both knew the treatment.

This was a 24-week, prospective, single-center, open-label, single-arm study.

What Was Measured

This study was performed to clarify the influence of the SGLT2 inhibitor ipragliflozin on beta-cell function assessed from the plasma intact proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.

Topics PubMed links to this paper include Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Glucose, Glucosides, Glycated Hemoglobin and Hyperglycemia.

Author keywords: Beta-cell function, Japanese, ipragliflozin, proinsulin/C-peptide ratio, sodium glucose cotransporter 2 inhibitors and type 2 diabetes.

What This Means in Plain Language

The paper is an open-label study of C-Peptide in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Expert opinion on pharmacotherapy), a journal based in England.

More context: the C-Peptide compound page, all human trials.